Andere Sprachen CNS Pharmaceuticals, Inc.

Aktien

A3D2GF

US18978H2013

CNSP

Verzögert Nasdaq Andere Börsenplätze 22:00:00 23.04.2024			% 5 Tage	% 1. Jan.
0.21 ^USD	+5.47%		+0.72%	-83.46%

23.04.	Transcript : CNS Pharmaceuticals, Inc. - Special Call
01.04.	CNS Pharmaceuticals, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

CNS Pharmaceuticals to Present at the LSX World Congress 2024	14:52
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break, the CNSP Opportunity	23.04.
CNS Pharmaceuticals to Present at Two Investor Conferences in April	02.04.
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
CNS Pharmaceuticals, Inc. Approves the Appointments to its Board Committees	27.02.
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday on Caution Ahead of Fed Meeting, Tech Earnings	30.01.
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering	30.01.
CNS Pharmaceuticals Prices $4 Million Offering; Shares Fall Pre-Bell	30.01.
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors	19.01.
CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors	18.01.
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	18.01.
CNS Pharmaceuticals, Inc. Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	17.01.
CNS Pharmaceuticals : Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin - Form 8-K	18.12.
CNS Pharmaceuticals, Inc. Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin	18.12.
How CNS Pharmaceuticals Is Taking a Different Approach to Find a Treatment for Glioblastoma, a Cancer with a Poor Prognosis and No Cure	07.12.
CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy	22.11.
CNS Pharmaceuticals to Release Interim Data by the End of the Year for Potential Glioblastoma Drug Candidate	17.11.
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study before Year End	16.11.
CNS Pharmaceuticals : Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End - Form 8-K	15.11.
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen CNS Pharmaceuticals, Inc.

Aktien

A3D2GF

US18978H2013

CNSP

Andere Sprachen

Filter